TY - JOUR T1 - <em>MGMT</em> Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 437 LP - 446 DO - 10.21873/cgp.20102 VL - 15 IS - 6 AU - LENE E. JOHANNESSEN AU - PETTER BRANDAL AU - TOR ÅGE MYKLEBUST AU - SVERRE HEIM AU - FRANCESCA MICCI AU - IOANNIS PANAGOPOULOS Y1 - 2018/11/01 UR - http://cgp.iiarjournals.org/content/15/6/437.abstract N2 - Background: Although methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no consensus exists as to which assay is best for its detection. Materials and Methods: Methylation of MGMT promoter was examined by methylation-specific polymerase chain reaction (MSP), quantitative real-time MSP, methylation-sensitive high-resolution melting analysis, and two commercial pyrosequencing (PSQ) kits. Survival was compared among 48 patients with glioblastoma according to assay results. Results: Only PSQ and MSP significantly separated patients who benefited from temozolomide, with PSQ being the superior method. For PSQ analysis, the cut-off value that best correlated with prognostic outcome was 7% methylation of MGMT. Median survival in patients with MGMT promoter methylation above this cut-off value was 7.8 months longer compared to those with less than 7% methylation. Two-year overall survival for the two groups was 42% and 7.4%, respectively. Conclusion: PSQ is the method of choice for MGMT promoter methylation analysis in routine clinical practice. ER -